The Adaptive Aerosol Delivery (AAD) Technology: Past, Present, and Future

Denyer, John; Dyche, Tony

doi:10.1089/jamp.2009.0791

Cited by 63 publications

(62 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Philips: In 2002, the Omron Healthcare Ltd aerosol generation technology was licensed by Profile Therapeutics Ltd (which later became Respironics Respiratory Drug Delivery [UK] Ltd) and integrated into their third-generation Adaptive Aerosol Delivery (AAD) device, the I-neb AAD System nebulizer [4], which was launched in 2004 [18]. This device incorporated the superior efficiency of mesh technology with the 'intelligent' AAD technology.…”

Section: Mesh Nebulizer Manufacturersmentioning

confidence: 99%

“…This device incorporated the superior efficiency of mesh technology with the 'intelligent' AAD technology. It released aerosol only into the patient's inhalation, based on the inhalation length predicted by the AAD algorithm from previous inhalation data [18,19]. The advanced technology provided patients with feedback and also allowed the delivery of precise doses with reduced wastage, thus reducing the amount of drug required to be loaded into the device in order to deliver an effective dose to the patient.…”

Section: Mesh Nebulizer Manufacturersmentioning

confidence: 99%

“…The single pass aerosol generation with no need for baffles has also resulted in reduced residual volume, fast nebulization times and long battery life. The minimal residual volume of around 100 μl [6,18,42] compared with the large volume of liquid that remains within a jet [4,6,15,43] or ultrasonic nebulizer cup [6], has been a key advantage in the successful commercialization of many of the mesh nebulizer brands. This has allowed a reduction in fill volumes in comparison with previous nebulizers.…”

Section: Advantages Of Mesh Nebulizer Designmentioning

confidence: 99%

See 2 more Smart Citations

Mesh Nebulizers have Become the First Choice for New Nebulized Pharmaceutical Drug Developments

Pritchard

Hatley

Denyer³

et al. 2018

Ther. Deliv.

Self Cite

112

View full text Add to dashboard Cite

In the 24 years since first being marketed, the mesh nebulizer has been developed by five main manufacturers into a viable solution for the delivery of high-value nebulized drugs. Mesh nebulizers provide increased portability, convenience and energy efficiency along with similar lung deposition and increased ease of use compared with jet nebulizers. An analysis of EU and US clinical trial databases has shown that mesh nebulizers are now preferred over jet nebulizers for clinical trials sponsored by pharmaceutical companies. The results show a strong preference for the use of mesh nebulizers in trials involving high cost and niche therapy areas. Built-in capability to optimize the way patients use their mesh nebulizer and manage their disease will further increase uptake. [Formula: see text]

show abstract

Section: Mesh Nebulizer Manufacturersmentioning

confidence: 99%

Section: Mesh Nebulizer Manufacturersmentioning

confidence: 99%

Section: Advantages Of Mesh Nebulizer Designmentioning

confidence: 99%

See 1 more Smart Citation

Mesh Nebulizers have Become the First Choice for New Nebulized Pharmaceutical Drug Developments

Pritchard

Hatley

Denyer³

et al. 2018

Ther. Deliv.

Self Cite

112

View full text Add to dashboard Cite

show abstract

“…Commercial devices have been developed to guide or control patient breathing through nebulizers. (33,34) It should be understood that both central and peripheral deposition fractions, as well as their uniformity among parallel lung regions, will depend on an individual subject's lung volume and airway geometry, thus the effectiveness of any prescribed inhalation pattern (or particle size) in achieving regional targeting will be variable between subjects.…”

Section: Parameters Affecting Addmentioning

confidence: 99%

Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung

Darquenne

Fleming

Katz

et al. 2016

Journal of Aerosol Medicine and Pulmonary Drug Delivery

View full text Add to dashboard Cite

Development of a new drug for the treatment of lung disease is a complex and time consuming process involving numerous disciplines of basic and applied sciences. During the 2015 Congress of the International Society for Aerosols in Medicine, a group of experts including aerosol scientists, physiologists, modelers, imagers, and clinicians participated in a workshop aiming at bridging the gap between basic research and clinical efficacy of inhaled drugs. This publication summarizes the current consensus on the topic. It begins with a short description of basic concepts of aerosol transport and a discussion on targeting strategies of inhaled aerosols to the lungs. It is followed by a description of both computational and biological lung models, and the use of imaging techniques to determine aerosol deposition distribution (ADD) in the lung. Finally, the importance of ADD to clinical efficacy is discussed. Several gaps were identified between basic science and clinical efficacy. One gap between scientific research aimed at predicting, controlling, and measuring ADD and the clinical use of inhaled aerosols is the considerable challenge of obtaining, in a single study, accurate information describing the optimal lung regions to be targeted, the effectiveness of targeting determined from ADD, and some measure of the drug's effectiveness. Other identified gaps were the language and methodology barriers that exist among disciplines, along with the significant regulatory hurdles that need to be overcome for novel drugs and/or therapies to reach the marketplace and benefit the patient. Despite these gaps, much progress has been made in recent years to improve clinical efficacy of inhaled drugs. Also, the recent efforts by many funding agencies and industry to support multidisciplinary networks including basic science researchers, R&D scientists, and clinicians will go a long way to further reduce the gap between science and clinical efficacy.

show abstract

“…A new device, Philips' i-neb, incorporating vibrating mesh technology, is designed for a portable device that can be applied outside the home (Denyer & Dyche, 2010). Respimat is a nebulization device, which makes it easy for patients who have difficulties to coordinate the inhalation and pMDI actuation.…”

Section: Nebulizersmentioning

confidence: 99%

Development of Nicotine Loaded Chitosan Nanoparticles for Lung Delivery

Wang¹

View full text Add to dashboard Cite

Cigarette smoking has become one of the leading causes of preventable deaths all over the world, causing a serious threat to human wellbeing and a tremendous economic burden to governments. The currently available treatment options for smoking cessation are not efficient. The pulmonary delivery of drugs by methods such as dry powder inhaler (DPI) has been recognized as one of the most efficient routes of drug delivery to the targeted area. The lung delivery of nicotine in this way would be expected to mimic the effects of tobacco smoking and could significantly reduce the negative health effects of smoking that result from nicotine addiction.The aim of this study is to develop nanoparticles with controlled physicochemical properties using biodegradable polymer of chitosan (CS) loaded with nicotine salt for pulmonary delivery as DPI formulations. The outcomes of this project are expected to be a safe and effective CS-based nicotine formulation for pulmonary delivery to treat nicotine dependence. This thesis specially addresses the research questions: (1) how to develop a feasible process to manufacture the nanoparticles suitable for pulmonary drug delivery using biodegradable polymer of CS containing nicotine salt; (2) how to develop an animal model for pulmonary drug delivery from DPI formulation using a nose-only inhalation device.The current therapeutic options for treatment of smoking addiction have been reviewed, and current advancements of technology in pulmonary drug delivery are summarised. Buccal administration of drugs exhibits a low oral bioavailability, and sublingual tablets and chewing gums can be swallowed before being absorbed.Although nasal spray of nicotine is a fast way to deliver nicotine into the bloodstream, Development of Nicotine Loaded Chitosan Nanoparticles for Lung Delivery iii the rate of absorption is still not as rapid as cigarette smoking. Therefore, it is proposed that delivery of nicotine with sustained drug release profile direct into the deep lung is likely to more effectively mimic the rapid effects of cigarette smoking on a physiological level, which could eliminate patient craving and allow the tapering of nicotine level over time to improve patients' compliance.Water in oil (w/o) emulsion crosslinking method has been used to fabricate nicotine hydrogen tartrate (NHT)-loaded CS nanoparticles which separate as solid microaggregates. The physicochemical properties of particles are characterized by a series of techniques. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) shows that the prepared particles are spherical in morphology with rough surface after loading CS particles with NHT. Dynamic Light Scattering (DLS)by Zetasizer determined nanoparticle size ranging from 167.6 nm to 411 nm, while DLS by Mastersizer demonstrated that the microaggregates of these nanoparticles are in the respirable range (<5µm). The surface positive charge as measured by zeta potential tends to decrease with increase of mass ratios of NHT to CS, which is in contr...

show abstract

The Adaptive Aerosol Delivery (AAD) Technology: Past, Present, and Future

Cited by 63 publications

References 15 publications

Mesh Nebulizers have Become the First Choice for New Nebulized Pharmaceutical Drug Developments

Mesh Nebulizers have Become the First Choice for New Nebulized Pharmaceutical Drug Developments

Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung

Development of Nicotine Loaded Chitosan Nanoparticles for Lung Delivery

Contact Info

Product

Resources

About